Article - Echosens

Choose your location

Choose your language

Validate

November 2025

Statement on the acceptance by the FDA of Echosens’ Letter of Intent for Drug Development Tool (DDT)

September 2025

A New Era for Liver Care: Prof. Dr. Jörn Schattenberg on the EC Approval of Rezdiffra™ for MASH

June 2025

A call for doubling the diagnostic rate of at-risk MASH

March 2025

New publication on our new technology Guided VCTE™

April 2024

Echosens statement on the passing of Dr. Stephen Harrison

April 2024

Revolutionizing Liver Disease Treatment: A Conversation with Dr. Naim Alkhouri about the First-ever Therapeutic for MASH

April 2024

Join us on World Liver Day 2024

October 2023

Turning Point report recommends using FibroScan^®

September 2023

Understanding the Nomenclature Shift in Fatty Liver Disease

June 2023

NICE Issues Landmark Guidance to Bring Routine Liver Scans to Primary Care Settings

Email
This field is for validation purposes and should be left unchanged.
Country*
Email*
By subscribing, I agree that Echosens collects and uses my data in accordance with the Privacy Policy.

Catégorie: Article

Statement on the acceptance by the FDA of Echosens’ Letter of Intent for Drug Development Tool (DDT)

A New Era for Liver Care: Prof. Dr. Jörn Schattenberg on the EC Approval of Rezdiffra™ for MASH

A call for doubling the diagnostic rate of at-risk MASH

New publication on our new technology Guided VCTE™

Echosens statement on the passing of Dr. Stephen Harrison

Revolutionizing Liver Disease Treatment: A Conversation with Dr. Naim Alkhouri about the First-ever Therapeutic for MASH

Join us on World Liver Day 2024

Turning Point report recommends using FibroScan^®

Understanding the Nomenclature Shift in Fatty Liver Disease

NICE Issues Landmark Guidance to Bring Routine Liver Scans to Primary Care Settings

Always be informed about liver health

Catégorie: Article

Statement on the acceptance by the FDA of Echosens’ Letter of Intent for Drug Development Tool (DDT)

A New Era for Liver Care: Prof. Dr. Jörn Schattenberg on the EC Approval of Rezdiffra™ for MASH

A call for doubling the diagnostic rate of at-risk MASH

New publication on our new technology Guided VCTE™

Echosens statement on the passing of Dr. Stephen Harrison

Revolutionizing Liver Disease Treatment: A Conversation with Dr. Naim Alkhouri about the First-ever Therapeutic for MASH

Join us on World Liver Day 2024

Turning Point report recommends using FibroScan®

Understanding the Nomenclature Shift in Fatty Liver Disease

NICE Issues Landmark Guidance to Bring Routine Liver Scans to Primary Care Settings

Always be informed about liver health

Turning Point report recommends using FibroScan^®